Amedisys (AMED)
(Delayed Data from NSDQ)
$99.31 USD
+0.81 (0.82%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $99.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMED 99.31 +0.81(0.82%)
Will AMED be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMED
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
Can BrightSpring's Q1 Strength Carry Through 2025 Headwinds?
Other News for AMED
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
Decoding Amedisys Inc (AMED): A Strategic SWOT Insight
Amedisys (AMED) Exceeds Q2 Revenue Expectations
Amedisys Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $621. ...
Amedisys Inc (AMED) Reports Q2 2025 Financial Results | AMED stock news